Amid a New York Times article about a drug company raising the price of a non-patented drug came this passage:
This is not the first time the 32-year-old Mr. Shkreli, who has a reputation for both brilliance and brashness, has been the center of controversy. He started MSMB Capital, a hedge fund company, in his 20s and drew attention for urging the Food and Drug Administration not to approve certain drugs made by companies whose stock he was shorting.
It reminds me of Bill Ackman's lobbying of regulators to act against Herbalife or MBIA while shorting those companies.